Abstract: Emerging as a major global health concern, metabolic dysfunction-associated steatohepatitis (MASH) is closely linked to obesity, type 2 diabetes, and other metabolic disorders. Advances in metabolic research have positioned glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a promising therapeutic option for MASH, extending their use beyond diabetes and obesity management. This article examines the …Read More >

The hepatobiliary system (comprised of the liver, gallbladder, and bile ducts) plays an important role in digestion and in the biotransformation and disposition of endogenous molecules and drugs. Hepatobiliary diseases range from minor infection or scarring to serious conditions such as cancer. At this year’s EASL conference, WuXi AppTec showcased our comprehensive platform of hepatobiliary-related …Read More >

Selecting preclinical in vivo models that are reflective of clinical outcome is a key challenge in the development of new therapies to treat fibrotic diseases.  To accelerate research focused on pulmonary, renal, and liver fibrosis, WuXi AppTec has established a series of in vivo models supported with anti-fibrotic efficacy data.  Our platform also includes a …Read More >

Animal studies may provide a close approximation to humans when addressing the key challenge of clinical translatability. In the preclinical setting, new insights into disease models and mechanisms are crucial to efficacy studies. In this webinar, Dr. Deming Xu, Chief Pharmacologist, Executive Director, and Head of In Vivo Pharmacology of WuXi AppTec Discovery Biology will …Read More >

In this case study, we demonstrate clinical relevance of the HFD+CCL4 (high-fat diet and carbon tetrachloride) NASH animal model. Improvement of hepatic fibrosis has been a challenging endpoint in NASH clinical trials and selecting animal models that show anti-fibrotic efficacy has been equally challenging for the preclinical development of new NASH drugs.  Our findings indicate …Read More >

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.  

The hepatic fibrosis has been the most challenging aspect in the animal models for nonalcoholic steatohepatitis (NASH). Although it could induced by nutritional (high-fat died with high cholesterol, methionine and choline deficient diet, etc), chemical (carbon tetrachloride, thioacetamide, α-naphthylisothiocyanate etc.), and surgical (bile duct ligation) means, the clinical relevance of the resulting fibrosis remains an …Read More >